Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.
2023
Dr Tawbi on Nivolumab Plus Relatlimab in Metastatic Melanoma
Hussein A. Tawbi, MD, PhD, professor, deputy chair, director, Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the 2-year findings from the phase 2/3 RELATIVITY-047 trial (NCT03470922) of nivolumab plus relatlimab-rmbw (Opdualag) in treatment-naïve patients with metastatic or unresectable melanoma.
ASCO 2023: Moderna and MSD’s vaccine/IO combo reduces chances of melanoma spreading
Moderna and MSD revealed an update on results demonstrating an improved distant metastasis-free survival (DMFS) when their mRNA vaccine was used in combination with Keytruda (pembrolizumab), at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Nivolumab Plus Relatlimab Demonstrates Consistent Benefit for Patients with Advanced Melanoma
Two-year follow-up data from the RELATIVITY-047 trial (NCT03470922) showed a continued benefit for patients with previously untreated, unresectable, or metastatic melanoma receiving nivolumab plus relatlimab (Opdualag) vs nivolumab (Opdivo) monotherapy supporting the use of the combination, according to Hussein A. Tawbi, MD, PhD.